Variant Immunomodulatory Proteins of the ICOS Ligand and Related Compositions and Methods
Patent Information
- Application Number
- EA202391557
- Authority / Receiving Office
- EA · EA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-10-18
- Filing Date
- 2018-10-17
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2038-10-17
Smart Images

Figure 00000218_0000 
Figure 00000218_0001 
Figure 00000219_0000
Abstract
Claims
1. A variant ICOS ligand (ICOSL) polypeptide comprising one or more amino acid modifications in an immunoglobulin superfamily (IgSF) domain of a reference ICOSL polypeptide, wherein the one or more amino acid modifications comprise N52A, N52C, N52D, N52G, N52K, N52L, N52M, N52Q, N52R, N52T, N52V, N52Y, N57A, N57D, N57E, N57F, N57H, N57K, N57L, N57M, N57P, N57Q, N57S, N57T, N57V, N57W, Q100A, Q100D, Q100G, Q100K, Q100L, Q100M, Q100N, Q100S, Q100T or Q100V with respect to the numbering of SEQ ID NO: 32; and where the reference ICOSL polypeptide is more resistant to protease cleavage compared to a wild-type ICOSL polypeptide and wherein said reference ICOSL polypeptide (i) is a truncated extracellular domain of ICOSL comprising a contiguous amino acid sequence comprising amino acids 1-112 and a C-terminal truncation of at least 25 amino acids relative to the sequence of the extracellular domain of ICOSL presented in SEQ ID NO: 32; or (ii) is altered in one or more amino acids corresponding to amino acids 204-209 relative to SEQ ID NO:
32.
2. The variant ICOSL polypeptide according to claim 1, wherein the C-terminal shortening is at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 125 amino acid residues.
3. A variant ICOSL polypeptide according to claim 1 or 2, wherein the reference ICOSL polypeptide is altered or has lost the protease cleavage site that is represented by amino acids 204-209 of SEQ ID NO:
32.
4. A variant ICOS ligand (ICOSL) polypeptide comprising an IgV domain or a specific binding fragment thereof, an IgC domain or a specific binding fragment thereof, or both domains, wherein the variant ICOSL polypeptide comprises one or more amino acid modifications in a reference ICOSL polypeptide or a specific binding fragment thereof corresponding to amino acid modifications selected from N52A, N52C, N52G, N52L, N52M, N52R, N52T, N52V, N57A, N57E, N57F, N57H, N57K, N57L, N57M, N57P, N57Q, N57S, N57T, N57V, N57W, Q100A, Q100D, Q100G, Q100L, Q100M, Q100N, Q100S, Q100T or Q100V relative to the numbering of SEQ ID NO:
32.
5. The variant ICOSL polypeptide of claim 4, wherein the reference ICOSL polypeptide comprises (i) the amino acid sequence shown in SEQ ID NO: 32, (ii) an amino acid sequence that has at least 95% sequence identity to SEQ ID NO: 32; or (iii) a portion of (i) or (ii) comprising an IgV domain or an IgC domain or specific binding fragments thereof, or both.
6. The variant ICOSL polypeptide of claim 4 or 5, wherein the variant ICOSL polypeptide comprises an IgV domain or a specific binding fragment thereof.
7. The variant ICOSL polypeptide of any one of claims 4 to 6, wherein the IgV domain or specific binding fragment thereof is the only ICOSL portion of the variant ICOSL polypeptide.
8. A variant ICOSL polypeptide according to any one of claims 1 to 7, wherein the reference ICOSL polypeptide comprises the amino acid sequence presented in SEQ ID NO:
545.
9. A variant ICOSL polypeptide according to any one of claims 1 to 7, wherein the reference ICOSL polypeptide consists of the amino acid sequence presented in SEQ ID NO:
545.
10. A variant ICOSL polypeptide according to any one of claims 1-3 and 8-9, wherein one or more amino acid modifications are at a position corresponding to position(s) 52, 57 or 100, relative to the numbering of SEQ ID NO:
32.
11. A variant ICOSL polypeptide according to any one of claims 1 to 10, wherein the variant ICOSL comprises one or more amino acid modifications that are N52L / N57H / Q100R and / or said polypeptide has the sequence presented in SEQ ID NO:
761.
12. A variant ICOSL polypeptide according to any one of claims 1 to 10, wherein the variant ICOSL comprises an amino acid modification which is N52D and / or said polypeptide has the sequence presented in SEQ ID NO:
548.
13. A variant ICOSL polypeptide according to any one of claims 1-10 and 12, wherein the reference ICOSL polypeptide is altered in one or more amino acids corresponding to amino acids 204-209, relative to SEQ ID NO: 32, and wherein: the change comprises a deletion of one or more contiguous amino acids corresponding to amino acids 204-209 relative to SEQ ID NO: 32; or the change comprises at least one amino acid substitution at one or both positions 207 and 208, corresponding to the positions presented in SEQ ID NO:
32.
14. The variant ICOSL polypeptide of claim 13, wherein at least one amino acid substitution is N207A, N207G, or L208G relative to the numbering of SEQ ID NO: 32, or a conservative amino acid substitution thereof.
15. The variant ICOSL polypeptide of any one of claims 1-10 and 12, wherein the variant ICOSL polypeptide exhibits reduced proteolytic cleavage when expressed from a cell, compared to the full-length extracellular domain of the variant ICOSL polypeptide when expressed from the same cell.
16. The variant ICOSL polypeptide of any one of claims 1 to 15, wherein the variant ICOSL polypeptide exhibits increased binding to the ectodomain(s) of ICOS and / or CD28 compared to the binding of a reference ICOSL polypeptide to the same ectodomain(s), optionally wherein the binding is increased by more than 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, or 60-fold.
17. The variant ICOSL polypeptide of any one of claims 1 to 16, wherein the variant ICOSL polypeptide comprises up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acid modifications, wherein the amino acid modifications are optionally amino acid substitutions, insertions and / or deletions.
18. A variant ICOSL polypeptide according to any one of claims 1 to 17, which is a soluble protein.
19. A variant ICOSL polypeptide according to any one of claims 1-18, wherein a variant ICOSL polypeptide that has lost the transmembrane domain or the intracellular signaling domain; and / or When expressed from a cell, the variant ICOSL polypeptide is not expressed on the cell surface.
20. A variant ICOSL polypeptide according to any one of claims 1 to 19, wherein the variant ICOSL polypeptide further comprises a transmembrane domain, optionally, wherein the variant ICOSL further comprises a cytoplasmic signaling domain associated with the transmembrane domain.
21. An immunomodulatory protein comprising a variant ICOSL polypeptide according to any one of claims 1 to 20 and a half-life extending fragment, wherein the half-life extending fragment comprises a multimerization domain, albumin, an albumin-binding polypeptide, Pro / Ala / Ser (PAS), a C-terminal peptide (CTP) of the beta subunit of human chorionic gonadotropin, polyethylene glycol (PEG), long unstructured hydrophilic amino acid sequences (XTEN), hydroxyethyl starch (HES), an albumin-binding small molecule, or a combination thereof.
22. The immunomodulatory protein of claim 21, wherein the half-life increasing fragment is or comprises a multimerization domain.
23. An immunomodulatory protein comprising a variant ICOSL polypeptide according to any one of claims 1-20 linked to a second polypeptide containing an immunoglobulin superfamily (IgSF) domain.
24. The immunomodulatory polypeptide of claim 23, wherein the IgSF domain of the second polypeptide exhibits increased binding to one or more of its cognate binding partners compared to an unmodified IgSF domain or a wild-type IgSF domain, optionally wherein the IgSF domain of the second polypeptide is capable of binding to a binding partner other than the partner specifically bound by the variant ICOSL polypeptide.
25. An immunomodulatory polypeptide according to any one of claims 23 or 24, wherein the IgSF domain of the second polypeptide is a tumor-localized fragment that binds to a ligand expressed on the tumor.
26. The immunomodulatory polypeptide of claim 25, wherein the ligand is B7H6 and / or wherein the IgSF domain is derived from NKp30.
27. An immunomodulatory protein according to any one of claims 21 and 23-26, wherein the immunomodulatory protein comprises a multimerization domain linked to one or both of the variant ICOSL polypeptide or the second polypeptide comprising an IgSF domain, optionally, wherein the multimerization domain is linked via a linker to one or both of the variant ICOSL polypeptide or the second polypeptide comprising an IgSF domain.
28. The immunomodulatory protein of claims 22 and 27, wherein the multimerization domain is the Fc region of an immunoglobulin.
29. An immunomodulatory protein according to any one of claims 21-22, 27 and 28, which is a dimer.
30. The immunomodulatory protein of claim 29, wherein the dimer is a homodimer.
31. The immunomodulatory protein of claim 29, wherein the dimer is a heterodimer.
32. The immunomodulatory protein of any one of claims 28 to 31, wherein the Fc region is human IgG1 or is a variant of the Fc region comprising one or more amino acid substitutions compared to wild-type human IgG1, optionally wherein the Fc region comprises the amino acid sequence presented in SEQ ID NO: 226, or a variant thereof, which exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO:
226.
33. An immunomodulatory protein according to any one of claims 26 to 32, wherein the Fc region exhibits one or more effector functions.
34. An immunomodulatory protein according to any one of claims 28 to 32, wherein the Fc region is a variant Fc region that exhibits one or more reduced effector functions compared to Fc from wild-type human IgG1.
35. The immunomodulatory protein of claim 34, wherein the Fc region variant comprises one or more amino acid substitutions selected from N297G, E233P / L234V / L235A / G236del / S267K or L234A / L235E / G237A, where the residue is numbered according to the EU index according to Kabat.
36. The immunomodulatory protein of claim 35, wherein the variant Fc region further comprises an amino acid substitution C220S, wherein the residues are numbered according to the EU index according to Kabat and / or said Fc region comprises K447del, wherein the residue is numbered according to the EU index according to Kabat.
37. The immunomodulatory protein of claim 35 or 36, wherein the Fc region comprises the amino acid sequence presented in SEQ ID NO:476, SEQ ID NO:632, SEQ ID NO:478, SEQ ID NO:634, SEQ ID NO:477, SEQ ID NO:633, SEQ ID NO:474 or SEQ ID NO:
637.
38. An immunomodulatory protein according to any one of claims 28-37, wherein the variant ICOSL polypeptide is linked via a linker to an Fc region, optionally, wherein the linker comprises from 1 to 10 amino acids.
39. An immunomodulatory protein according to any one of claims 23-38, wherein the variant ICOSL polypeptide and the IgSF domain of the second polypeptide are connected by a linker.
40. An immunomodulatory protein according to claims 27-39, wherein the multimerization domain is linked via a linker to one or both of the variant ICOSL polypeptide or the second polypeptide comprising an IgSF domain.
41. The immunomodulatory protein of any one of claims 38-40, wherein the linker is AAA, G4S (SEQ ID NO: 636), (G4S)2 (SEQ ID NO: 229), 3x GGGGS (SEQ ID NO: 228) or GSGGGGS (SEQ ID NO: 635).
42. A conjugate comprising a variant ICOSL polypeptide according to any one of claims 1-20 or an immunomodulatory protein according to any one of claims 21-41 and a heterologous moiety, wherein the heterologous moiety is a targeting moiety that specifically binds to a molecule on the surface of a cell.
43. The conjugate of claim 42, wherein the conjugate is a hybrid protein.
44. The conjugate of claim 42, wherein the targeting moiety specifically binds to a molecule on the surface of an immune cell, optionally wherein the immune cell is an antigen-presenting cell or a lymphocyte.
45. The conjugate of claim 42, wherein the targeting moiety is a tumor-localizing moiety that binds to a molecule on the surface of the tumor.
46. The conjugate of claims 42-45, wherein the targeting moiety is an antibody or antigen-binding fragment, optionally wherein the antibody is selected from cetuximab, panitumumab, zalutumumab, nimotuzumab, trastuzumab, adotrastumumab, emtansine, tositumomab (Bexxar®), rituximab (Rituxan, Mabthera), ibritumomab tiuxetan (Zevalin), daclizumab (Zenapax), gemtuzumab (Mylotarg), alemtuzumab, a Fab fragment of CEA-scan, monoclonal antibody OC125, ab75705, B72.3, bevacizumab (Avastin®), afatinib, axitinib, bosutinib, cabozantinib, ceritinib, crizotinib, dabrafenib, dasatinib, dinutuximab, erlotinib, everolimus, ibrutinib, imatinib, lapatinib, lenvatinib, nilotinib, olaparib, olaratumab, palbociclib, pazopanib, pertuzumab, ramukirumab, regorafenib, ruxolitinib, sorafenib, sunitinib, temsirolimus, trametinib, vandetanib, vemurafenib, vismodegib, basiliximab, ipilimumab, nivolumab, pembrolizumab, MPDL3280A, pidilizumab (CT-011), AMP-224, MSB001078C or MEDI4736, BMS-935559, LY3300054, atezolizumab, avelumab or durvalumab, or is an antigen-binding fragment thereof.
47. A monovalent hybrid protein containing: (a) a variant ICOSL polypeptide according to any one of claims 1 to 20; and (b) a label for detecting or purifying the variant ICOSL polypeptide.
48. The hybrid protein of claim 47, wherein the detection or purification tag is selected from a polyhistidine (His) tag, a FLAG tag, a Myc tag, or a fluorescent protein tag.
49. A nucleic acid molecule encoding a variant ICOSL polypeptide according to any one of claims 1 to 20.
50. A vector containing a nucleic acid molecule according to claim 49.
51. A cell containing a nucleic acid molecule according to claim 49 or a vector according to claim 50.
52. A method for producing an immunomodulatory protein containing a variant ICOSL polypeptide, comprising introducing a nucleic acid molecule according to claim 49 or a vector according to claim 50 into a host cell under conditions for expressing the protein in the cell.
53. The method according to claim 52, wherein the cell is a mammalian cell.
54. The method according to claim 52 or 53, wherein the cell is a Chinese hamster ovary (CHO) cell or a derivative thereof, optionally wherein the cell is CHO DG44.
55. The method according to any one of paragraphs 52-54, further comprising isolating or purifying the protein from the cell.
56. An immunomodulatory protein obtained by the method according to any of paragraphs 52-55.
57. A pharmaceutical composition comprising a protein comprising a variant ICOSL polypeptide according to any one of claims 1-20 or an immunomodulatory protein according to any one of claims 21-41.
58. The composition of claim 57, wherein the protein or immunomodulatory protein is purified from Chinese hamster ovary cells or a derivative thereof.
59. An engineered cell comprising a variant ICOSL polypeptide according to any one of claims 1-20, an immunomodulatory protein according to any one of claims 21-41, a conjugate according to any one of claims 42-46, a hybrid protein according to any one of claims 47-48, a nucleic acid molecule according to claim 49, or a vector according to claim 50.
60. The engineered cell of claim 59, wherein the variant ICOSL polypeptide, immunomodulatory protein, or fusion protein is secreted from the engineered cell or wherein the engineered cell comprises a variant ICOSL polypeptide that is a membrane protein expressed on the surface of the cell.
61. An engineered cell according to any one of claims 59-60, wherein the cell is an immune cell, preferably wherein the immune cell is an antigen-presenting cell (APC) or a lymphocyte.
62. An engineered cell according to any one of claims 59-61, further comprising a chimeric antigen receptor (CAR) or an engineered T cell receptor.
63. An infectious agent comprising a nucleic acid molecule encoding a variant ICOSL polypeptide according to any one of claims 1-20, or an immunomodulatory protein according to any one of claims 21-41, a conjugate according to any one of claims 42-46 or a hybrid protein according to any one of claims 47-48, a nucleic acid molecule according to claim 49 or a vector according to claim 50.
64. A pharmaceutical composition comprising a variant ICOSL polypeptide according to any one of claims 1-20, an immunomodulatory protein according to any one of claims 21-41, a conjugate or fusion protein according to any one of claims 43-48, a nucleic acid molecule according to claim 49 or a vector according to claim 50, or an engineered cell according to any one of claims 59-62 or an infectious agent according to claim 63, optionally containing a pharmaceutically acceptable excipient.
65. A method for modulating an immune response in a subject, comprising administering a pharmaceutical composition according to claim 64 to the subject.
66. A method of treating a disease or condition in a subject, comprising administering a pharmaceutical composition according to claim 64 to the subject.
67. The method according to claim 65 or 66, wherein the administration reduces the immune response in the subject.
68. The method according to claim 66 or 67, wherein the disease or condition is an inflammatory or autoimmune disease or condition.
69. A vial for use in the method according to paragraphs 65-68, comprising the pharmaceutical composition according to paragraph 64.
70. A kit for use in the method according to paragraphs 65-68, comprising a pharmaceutical composition according to paragraph 64 or a vial according to paragraph 69.
